Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics is poised for strong growth in the future with their innovative non-invasive tests and partnerships with healthcare providers. Their current backlog and sufficient cash reserves give them a strong financial foundation for future development. Upcoming catalysts, such as securing Medicare coverage and expanding into the large blue market, provide potential for significant revenue growth and market expansion.

Bears say

Lucid Diagnostics is facing numerous challenges in its efforts to become profitable, as evidenced by its less-than-stellar performance in its most recent quarter. The company's dependence on Medicare coverage for its products, specifically EsoGuard, presents a significant risk should coverage not materialize as expected. Additionally, Lucid Diagnostics has yet to establish a strong sales force and expand its test volumes in traditional settings, limiting its potential for growth. Furthermore, the company's valuation is a major concern, as it currently trades at a high multiple which may be difficult to sustain without strong revenue growth and profitability. Without a solid foundation for sustainable growth, Lucid Diagnostics' stock may continue to underperform in the market.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Sep 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.